about
Protease inhibition as new therapeutic strategy for GI diseasesMechanisms Underlying the Regulation of Innate and Adaptive Immunity by Vitamin DAntimicrobial proteins in intestine and inflammatory bowel diseasesThe "Vampirome": Transcriptome and proteome analysis of the principal and accessory submaxillary glands of the vampire bat Desmodus rotundus, a vector of human rabiesCirculating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblastsVarious forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis.Dehydroandrographolide enhances innate immunity of intestinal tract through up-regulation the expression of hBD-2Blastocystis Isolate B Exhibits Multiple Modes of Resistance against Antimicrobial Peptide LL-37.Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptorInflammatory signals that regulate intestinal epithelial renewal, differentiation, migration and cell death: Implications for necrotizing enterocolitis.Hepcidin expression in colon during trinitrobenzene sulfonic acid-induced colitis in rats.A randomized controlled trial on the effect of vitamin D3 on inflammation and cathelicidin gene expression in ulcerative colitis patientsIdentification of low oxygen-tolerating bacteria in prostate secretions of cancer patients and discussion of possible aetiological significance.Exogenous murine antimicrobial peptide CRAMP significantly exacerbates Ovalbumin-induced airway inflammation but ameliorates oxazolone-induced intestinal colitis in BALB/c mice.Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response.
P2860
Q26747722-D8AD5BE4-B4DC-48F5-A6C0-6F004EF18DC3Q26781318-80431995-CEDA-4799-889F-D8202EF51C8CQ27023239-441C1D6C-F1A4-48D9-AA07-202C8B74DF00Q28681336-15200E24-F6AE-4F50-B7B7-BAF350A4BC49Q33667766-3B26B821-5F31-4402-92E6-31CA3B7E6E2AQ34757218-6EF591B6-4959-45C8-8659-7329197AA739Q35022269-039A5D64-20F3-4C4B-AB0B-214E6A0F29A3Q35113922-189B96D7-1366-434A-9468-0703922028A5Q35902869-C6BC78DB-90E4-49F4-8824-E6D820477C05Q37129880-A964ADCD-5E5A-49FD-AFD8-738DC8969714Q37239135-C1C6D106-6F1A-4F93-8F62-E2F96037EDA7Q38188656-A91787A5-C467-479F-8256-1ACEFE946733Q38803196-C9D4014A-2956-4577-A60C-3E40BFD561EAQ40637403-62B095BA-9F3B-4AF2-9AE1-198951E78A90Q45777210-862DAC91-8323-45C3-A2B7-CCE9D784CF44Q47429893-DE2F8DB0-2836-4AEC-9C1B-62A2E16D010FQ52659607-5F0D8523-1568-4BB0-A4C4-154E229183B5
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antimicrobial peptides and colitis.
@en
type
label
Antimicrobial peptides and colitis.
@en
prefLabel
Antimicrobial peptides and colitis.
@en
P2093
P2860
P356
P1476
Antimicrobial peptides and colitis.
@en
P2093
Charalabos Pothoulakis
Hon Wai Koon
Samantha Ho
P2860
P356
10.2174/13816128130108
P577
2013-01-01T00:00:00Z